MAR 31, 2017 2:29 PM PDT

New Multiple Sclerosis Drug Wins FDA Approval

WRITTEN BY: Xuan Pham

The FDA recently approved the first drug for the treatment of relapsing forms of multiple sclerosis (MS). The announcement marks a significant achievement, which is expected to help the 400,000 MS patients in the US.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”

The drug is known on the market as Ocrevus (ocrelizumab), and it works by weakening the immune system. In particular, IV infusions of Ocrevus prevent the B cells from attacking the protective myelin covers.

Tested in patients with both forms of MS (the progressive form and the relapsing remitting form), Ocrevus seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The drug is so much more effective at shutting down inflammation," said David Hafler, an MS expert from the Yale School of Medicine.

Side effects associated with Ocrevus include infusion-related reactions, such as skin irritation, flushing, shortness of breath, and nausea. In addition, upper respiratory tract infections were among the most common side effect seen with the drug in both forms of MS.

Patients eager to be treated with Ocrevus will have to wait just a few more weeks. Furthermore, they should also be aware that this drug comes with a hefty price tag of $65,000 per year. Though the cost is substantial, it is reportedly on par with approved drugs for the other forms of MS.

Additional sources: CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 16, 2020
Microbiology
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
AUG 16, 2020
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
Bacteria in the gut have a powerful influence on our health, in part because all of those microbes have genes of their o ...
AUG 27, 2020
Clinical & Molecular DX
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
AUG 27, 2020
Genetic Tool Predicts Breast Cancer Risk in Women of Asian Ancestry
  Many diseases such as breast cancer have both a strong genetic component, coupled with a variety of environmental ...
SEP 07, 2020
Cancer
Identifying Robust Tumor Features for Better Radiomics
SEP 07, 2020
Identifying Robust Tumor Features for Better Radiomics
With the advancement of technology comes the renovation of classical medical techniques. Diagnostic is one of the areas ...
SEP 28, 2020
Cancer
A New Transcriptomics Program in the Works Glioma Diagnosis
SEP 28, 2020
A New Transcriptomics Program in the Works Glioma Diagnosis
The future of medicine is “personalized healthcare.” However, testing remains a critical hurdle researcher&r ...
OCT 06, 2020
Clinical & Molecular DX
A Smart Tattoo That Could Save Your Life
OCT 06, 2020
A Smart Tattoo That Could Save Your Life
Color-changing tattoos, powered by nanotechnology, that sense imbalances in your biochemistry providing a visual signal ...
NOV 05, 2020
Clinical & Molecular DX
Digging DEEP into Metabolomic Space
NOV 05, 2020
Digging DEEP into Metabolomic Space
Metabolomics is an umbrella term encompassing lipidomics and the study of smaller polar metabolites.  As such, more ...
Loading Comments...